ESR1 and breast cancer: In additionally, PP2A inhibition has been found markedly associated with negative ER and PR expression in breast cancer patients [128], and further determines doxorubicin resistance in breast cancer cells, which are re-sensitized after pharmacological restoration of PP2A activation using FTY720, an FDA-approved immune-suppressant drug [129].